摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

<(Dimethylamino)methylene>nitromethane | 87446-70-6

中文名称
——
中文别名
——
英文名称
<(Dimethylamino)methylene>nitromethane
英文别名
(Z)-N,N-dimethyl-2-nitroethen-1-amine;1-nitro-2-dimethylaminoethane;2-dimethylamino-1-nitroethene;Z-1-dimethylamino-2-nitroethylene;(Z)-N,N-dimethyl-2-nitroethenamine
<(Dimethylamino)methylene>nitromethane化学式
CAS
87446-70-6
化学式
C4H8N2O2
mdl
——
分子量
116.12
InChiKey
JKOVQYWMFZTKMX-ARJAWSKDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.8
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    49.1
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:085ecffe4c519d450b8cd16311485239
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2021154665A1
    公开(公告)日:2021-08-05
    Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    根据公式I,化合物可用作Toll样受体7(TLR7)的激动剂。这些化合物可用于癌症治疗,特别是与抗癌免疫疗法药物结合使用,或作为疫苗佐剂。
  • N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
    申请人:Chen Zhaogen
    公开号:US20060009511A9
    公开(公告)日:2006-01-12
    The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.
    本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
  • N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
    申请人:Chen Zhaogen
    公开号:US20070099909A1
    公开(公告)日:2007-05-03
    The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.
    本发明提供了公式(I)的化合物,它们是5-HT6受体的拮抗剂。
  • N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor
    申请人:Eli Lilly and Company
    公开号:US07157488B2
    公开(公告)日:2007-01-02
    The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
    本发明提供了I式化合物及其药学上可接受的盐和制药组合物,其为5-HT6受体拮抗剂。本发明还提供了一种治疗与5-HT6受体有关的疾病的方法,包括精神分裂症、焦虑症、阿尔茨海默病和从年龄相关的认知衰退、轻度认知障碍和痴呆症中选择的认知障碍,该方法包括:向需要接受治疗的患者施用I式化合物的有效量。
  • N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
    申请人:Eli Lilly
    公开号:US08044090B2
    公开(公告)日:2011-10-25
    The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
查看更多